Co-founder, President and CEO
Michael Cardone leads the company’s efforts to achieve scientific and corporate milestones. His experience includes over 15 years of scientific and business management at early to mid-stage biotech companies. Prior to Eutropics, he was a scientific co-founder of Merrimack Pharmaceuticals, a Cambridge, MA based company (NASDQ trading symbol: MACK) where he worked with the starting team to develop the oncology program. Prior to this, he led a research team in the Department of Biology at MIT developing tools for small molecule drug target identification and validation. Dr. Cardone received a Ph.D. in protein trafficking from the University of California San Francisco and completed post-doctoral studies in apoptosis signaling at the Burnham Institute in La Jolla, CA.
Director of Clinical Diagnostics
Dr. Dettman is leading the development and implementation of CLIA certified diagnostic tests at Eutropics. He is a technical leader in oncology and personalized medicine with emphasis on biomarker utilization and novel diagnostic technology development. Prior to joining Eutropics, Dr. Dettman was a program leader in translational biomarker development and high content data acquisition and analysis at ApoCell in Houston, TX.
Dr. Dettman earned his Ph.D. at the Baylor College of Medicine where he discovered biomarker genes involved in leukemia. During his post-doctoral fellowship at MD Anderson, he studied the role of epigenetic modifications in epithelial and myeloid cancers.
Advisory Board Member
Dr. Miller is an accomplished leader with over 25 years of experience in drug and clinical development, biomarkers and diagnostics, personalized medicine and business development. Dr. Miller is currently Chief Technology Officer and Executive Vice president of Molecular MD in Cambridge, MA. Prior to that, he was Vice President and Head of Personalized Healthcare & Biomarker Strategy for AstraZeneca. He also previously was Vice President and General Manager of Genzyme Analytical Services, a division of Genzyme Genetics that was acquired by LabCorp in 2010. He sits on the Board of Directors of BioMarker Strategies, has served as Chair of the Personalized Medicine Task Force of the European Biopharmaceutical Enterprises, and is a member of the Clinical Sciences Committee of the Personalized Medicine Coalition.
Dr. Miller received his Ph.D. in Experimental Pathology from Roswell Park Memorial Institute. He completed his postdoctoral work in molecular hematology and viral leukemogenesis at Memorial Sloan Kettering Cancer Center and molecular genetics at the University of Miami, School of Medicine.
Advisory Board Member
Mr. Ung has provided business and operations leadership in emerging biomarker technologies for translational and clinical applications in oncology drug development for over 20 years. He has an extensive track record of successful partnering with biotech and pharmaceutical companies to develop biomarker assays for exploratory, pharmacodynamics and selection utilities, and is currently Chief Operating Officer at Ligacept, Oak Brook, IL, and a business advisor to STC Biologics. Previously, he was Vice President of Oncology Therapeutic Strategy at Quintiles where he directed the strategic development initiatives and led the implementation of new biomarker-related programs. Prior to joining Quintiles, he was Chief Operating Officer and co-founder of Targeted Molecular Diagnostics and previously served as Chairman of the Pathology Business Group at DAKO.
Mr. Ung has managed the development and commercialization of both the HercepTest® and pharmDx EGFR assays, used to identify patients for treatment with Herceptin and Erbitux, respectively. Mr. Ung graduated from Lewis and Clark College with a bachelor’s degree in chemistry and mathematics. He earned a master’s degree in chemistry from UC Berkeley and an MBA from the UCLA Anderson School of Management.
Dr. Andreeff is the Chief of Molecular Hematology and Therapeutics and the Paul and Mary Haas Chair in Genetics at-sm Anderson Cancer Research Center, University of Texas. He is a renowned expert in pre-clinical and clinical studies of therapies for hematological disease, and most notably, Acute Myeloid Leukemia. His approaches include the development of cytokine-chemotherapy combinations; the development of multiple drug resistance (MDR)-blocking strategies in the laboratory and clinical trials; the study of cell proliferation in vivo with modified nucleotides; a comprehensive analysis of pathways of cell proliferation and apoptosis in AML patients during and after induction chemotherapy; and the development of strategies to modulate apoptotic pathways in leukemias utilizing gene therapy, anti-sense oligonucleotides, retinoids and Bcl-2 family-modulating small molecules.
Dr. Andreeff received his M.D. and Ph.D. degrees from the University of Heidelberg where he completed his residencies in surgery, medicine, and gynecology. He completed fellowships in Hematology Oncology at the University of Mainz Medical School and at Memorial Hospital in New York.
Dr. Anderson is the Chief in the Division of Hematological Neoplasia, the Director of the James Lipper Multiple Myeloma Center, and the Kraft Professor of Medicine at the Harvard Medical School, Dana Farber Cancer Research Institute. He earned his medical degree from the Johns Hopkins Medical School in 1977 and trained in internal medicine at Johns Hopkins Hospital. Thereafter, he completed training in hematology, medical oncology and tumor immunology at the Dana Farber Cancer Institute.
Dr. Anderson serves as Vice Chair of the Joint Program in Transfusion Medicine at DFCI. He also serves as Chair of the National Comprehensive Cancer Network (NCCN) Multiple Myeloma Clinical Practice Guidelines Committee, is a Cancer and Leukemia Group B Principal Investigator, serves on the Board of Scientific Advisors of the International Myeloma Foundation, and sits on the Board of Directors and serves as Chair of the Scientific Advisory Board of the Multiple Myeloma Research Foundation and of the Leadership Committee of the Multiple Myeloma Research Consortium. Dr. Anderson is a Doris Duke Distinguished Clinical Research Scientist. His numerous awards include the 2001 Charles C. Lund Award of the American Red Cross Blood Services, the 2003 Waldenstrom’s Award for research in plasma cell dyscrasias, and the 2004 Johnson & Johnson Focused Giving Award for Setting New Directions in Science and Technology.
Dr. D’Andrea is the Alvan T. and Viola D. Fuller American Cancer Society Professor of Radiation Oncology, Harvard Medical School, Dana Farber Cancer Research Center where he is also scientific director of the Molecular Diagnostics Laboratory. Dr. D'Andrea obtained his M.D. from Harvard Medical School and completed a pediatric residency training at the Children's Hospital of Philadelphia. He performed his post-doctoral research training at the Whitehead Institute for Biomedical Research in Cambridge, MA. At that time, he and his collaborators cloned the gene for the erythropoietin receptor, a major regulator of normal human blood cell formation. After completing his research training, Dr. D'Andrea joined the Harvard Medical School faculty. Dr. D'Andrea is internationally known for his research in the fields of human blood cell formation and cancer susceptibility. He directs a laboratory at the Dana Farber Cancer Institute and is the Co-Director of the Clinical Gene Therapy Center at Children's Hospital, Boston. Dr. D'Andrea is the recipient of numerous awards, including the Lucille P. Markey Scholar Award, the American Academy of Pediatrics Award for Excellence in Research, and the Stohlman Scholar Award from the Leukemia and Lymphoma Society.
Professor Wagner is the Elkan Blout Professor of Biological Chemistry and Molecular Pharmacology Harvard Medical School. Dr. Wagner is a recognized world expert on structural characterization for proteins and multiprotein complexes, employing NMR spectroscopic methodology, mathematical models, and biological techniques. Dr. Wagner’s lab is considered an authority on applying NMR spectroscopy to the elucidation of protein structure, protein-protein interactions and small molecule screening. In addition, the lab is particularly skilled in NMR spectroscopy-based analysis of larger proteins (> 35 - 40 kDa), and has published several studies for improving and optimizing NMR spectroscopic methods for studying this class of polypeptides. Moreover, he has championed the use of NMR spectroscopy for characterizing the perturbations that occur following protein-protein or protein-nucleic acid associations, as well as in-cell NMR spectroscopy. He has explored structure/function relationships for protein constituents of eukaryotic protein translation, apoptosis, T cells, and various other cellular processes. Prof. Wagner earned his Ph.D. from the ETH in Zurich, Switzerland, and his undergraduate degree in physics from the Technical University in Munich, Germany.